hotspot -WSS

hotspot

author：knowledge 2025-10-02 23:32:03 - browse：137

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： What causes osteoarthritis? Researchers study link to brain protein

WSS

The inclusion problem at the heart of rehabilitation research

Google and Epic fight stronger regulation of AI in health care

STAT Virtual Event: The State of Biosimilars: What to Watch

Cosmetics set for new safety regulation. Why the industry is on board

Immunocompromised patients offer clues on chronic Covid

How Medicaid coverage policies for immigrants impact new moms

leisure time

hotspot

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

Anesthesiologist group: stop taking Ozempic before surgery

Custom gene therapy hints at new path for rare disease treatments

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Heart attack and stroke risk calculators need revising

Sanofi seeks simpler, safer CRISPR sickle cell cure

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare to cover more brain scans for Alzheimer’s patients

New air purifier tech could be key to improving indoor air quality

How dance can help nurses traumatized by Covid

knowledge

Head of FDA's diagnostics center, who led through Covid, retires

Pumping milk in bathrooms at health conferences is common

Mass General, Mayo Clinic look to monetize custom

High breast density mammograms need follow

How dance can help nurses traumatized by Covid

Google and Epic fight stronger regulation of AI in health care

knowledge

Wikipedia

hotspot

focus